Nevertheless, the PI3K/Akt signaling cascade remains a rational target of interest in MM [29, 30, 31] and multiple other cancers [32, 33, 34, 35], with several Akt inhibitors in ongoing clinical development either alone or in combination regimens [32, 36, 37, 38, 39], and preclinical data demonstrating the validity of this mechanism of action with perifosine and other agents both in hematological malignancies and solid tumors [40, 41, 42, 43]. This evidence concerns the gene AKT1 and hematologic disorder.